export default function LinaclotideOverviewPanel() {
  return (
    <div className="reta-overview">

      <p className="reta-overview__opener">
        Linaclotide is an FDA-approved prescription drug for two specific conditions: IBS with constipation and chronic idiopathic constipation. It works directly in the gut lining, is not absorbed into the bloodstream, and has no systemic or enhancement application &mdash; by design. If you have IBS-C or chronic constipation that hasn&rsquo;t responded to the basics, this is one of the most targeted and well-evidenced options available. There is one hard rule: it must be kept away from young children.
      </p>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 1</div>
        <h3 className="reta-overview__profile-heading">The Person with IBS-C &mdash; Constipation, Bloating, and Abdominal Pain</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I have IBS with constipation. My doctor mentioned Linzess but I want to understand what it actually does and whether the diarrhea side effect is going to make my life worse.&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re on it</p>
        <ol className="reta-overview__profile-why">
          <li><strong>It addresses both the constipation and the pain at the same time</strong><br />Most constipation treatments just add fluid to the bowel. Linaclotide does that too, but it also directly reduces visceral pain sensitivity &mdash; the reason IBS feels so uncomfortable even when you&rsquo;re not in a flare. It activates a receptor on the inner surface of the intestinal wall that produces a signaling molecule, which then calms down the pain-sensing nerve fibers underneath. This dual effect is why it has FDA approval specifically for IBS-C and not just constipation.</li>
          <li><strong>It stays in the gut and doesn&rsquo;t enter your bloodstream</strong><br />The drug is designed to be degraded in the intestinal lumen before it can be absorbed. That means it doesn&rsquo;t circulate through your body, it doesn&rsquo;t interact with most other medications, and it doesn&rsquo;t affect your liver or kidneys. The trade-off is it can only help your gut &mdash; but for a gut condition, that&rsquo;s the point.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">Diarrhea is the most common side effect and it&rsquo;s most likely in the first week. It&rsquo;s not a sign something is wrong &mdash; it&rsquo;s the drug doing what it does, just more than you want. Taking it 30 minutes before your first meal on an empty stomach helps. If diarrhea is severe, taking a break and restarting is the standard guidance &mdash; not adjusting the dose, since Linzess only comes in fixed capsule strengths. The abdominal pain benefit takes longer to show up than the constipation benefit &mdash; give it 4&ndash;6 weeks before judging whether it&rsquo;s helping your pain. Net: well-evidenced for both symptoms of IBS-C; the diarrhea risk is real but manageable for most people.</p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 2</div>
        <h3 className="reta-overview__profile-heading">The Gut Health Curious Person &mdash; Understanding Secretagogues and What Works</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I&rsquo;ve been reading about gut peptides and saw linaclotide mentioned alongside BPC-157 and KPV. Is this the same category or something different?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why it&rsquo;s worth understanding</p>
        <ol className="reta-overview__profile-why">
          <li><strong>It&rsquo;s a synthetic peptide that mimics the gut&rsquo;s own signaling molecules</strong><br />Your intestinal lining makes two peptides called guanylin and uroguanylin that help regulate how much fluid is in your bowel and how quickly things move. Linaclotide is an engineered 14-amino-acid peptide that activates the same receptor these natural peptides do &mdash; but it&rsquo;s more potent and stays in the gut longer. This is the same design philosophy as KPV for gut inflammation: a peptide engineered to act locally without systemic effects.</li>
          <li><strong>It has robust human trial data that most gut peptides don&rsquo;t</strong><br />Unlike most peptides discussed in wellness communities, linaclotide has gone through Phase 3 clinical trials with thousands of participants, FDA review, and post-market safety monitoring. Its mechanism, efficacy, and safety profile are characterized to a degree that research peptides simply are not. Understanding what a well-evidenced gut peptide looks like helps calibrate expectations for investigational ones.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">Linaclotide is only useful if you have IBS-C or chronic constipation &mdash; it&rsquo;s not a general gut health optimization tool and there&rsquo;s no enhancement angle because it isn&rsquo;t absorbed. The comparison to community gut peptides like KPV or BPC-157 is informative precisely because linaclotide shows what &ldquo;properly evidenced&rdquo; looks like: FDA trials, human efficacy data, characterized safety signals. Net: not a biohacking compound, but an important reference point for what rigorous gut peptide pharmacology looks like.</p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 3</div>
        <h3 className="reta-overview__profile-heading">The GI Physiology Biohacker &mdash; Luminal Peptide Engineering and the Pain-Secretion Dual Mechanism</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I want to understand the GC-C receptor cascade and how cGMP production achieves both luminal fluid secretion and visceral pain reduction through separate downstream pathways.&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why it&rsquo;s worth understanding</p>
        <ol className="reta-overview__profile-why">
          <li><strong>The dual mechanism operates through a single receptor using downstream pathway divergence</strong><br />Linaclotide activates GC-C receptors on intestinal epithelial cells, producing intracellular cGMP. That cGMP then activates two separate effectors: CFTR chloride channels (driving fluid and chloride secretion into the lumen) and a separate diffusion pathway where cGMP passes through into subepithelial afferent neurons, directly reducing their excitability. One receptor activation, one second messenger, two therapeutic outcomes &mdash; fluid secretion and pain relief &mdash; through pathway divergence downstream of cGMP. This is a clean example of signal bifurcation in peptide pharmacology.</li>
          <li><strong>The engineered GI instability is the safety mechanism, not a limitation</strong><br />Linaclotide is deliberately designed to be rapidly degraded in the intestinal lumen into an active metabolite that is itself not absorbed. GC-C receptors are expressed in the kidney, lung, and brain &mdash; systemic linaclotide would have off-target effects in these organs. The molecular engineering that restricts it to luminal activity is the entire safety design. This is a model for how targeted luminal peptide pharmacology can be achieved: build degradability into the molecule rather than relying on formulation tricks alone.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">For a biohacker without IBS-C or chronic constipation, linaclotide is purely a reference compound &mdash; there is no off-label enhancement use because it isn&rsquo;t systemically bioavailable. The interesting questions it raises are about how to design other luminal peptides with built-in degradability. Plecanatide is the comparison compound: same receptor, structurally an uroguanylin analog, pH-sensitive activity that may concentrate effect in the small intestine rather than the colon. The mechanistic comparison between the two GC-C agonists is the most interesting pharmacological exercise in this space. Net: no self-administration enhancement use; substantial value as a model of targeted luminal peptide design.</p>
      </div>

      <div className="reta-overview__bottom">
        <p className="reta-overview__bottom-heading">The honest bottom line</p>
        <div className="reta-overview__bottom-cols">
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What Linaclotide is NOT</p>
            <ul className="reta-overview__bottom-list">
              <li>Not a systemic drug &mdash; it is not absorbed into the bloodstream by design; there is no systemic or enhancement pharmacology</li>
              <li>Not a general gut health supplement &mdash; it is a prescription drug for two specific diagnosed conditions</li>
              <li>Not safe for children under 6 &mdash; this is an absolute contraindication with a black box warning; treat it like a locked medication around young children</li>
              <li>Not a quick pain fix &mdash; the constipation effect is rapid; the abdominal pain benefit takes weeks to develop</li>
              <li>Not adjustable mid-treatment &mdash; it comes in fixed capsule strengths; dose interruption rather than reduction is the management approach for diarrhea</li>
            </ul>
          </div>
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What makes it interesting</p>
            <ul className="reta-overview__bottom-list">
              <li>One of the only drugs approved for both the constipation and the abdominal pain of IBS-C, through a single receptor mechanism with downstream pathway divergence</li>
              <li>A model of engineered luminal peptide pharmacology &mdash; deliberately designed for GI-local action with built-in instability to prevent systemic absorption</li>
              <li>FDA-approved with large Phase 3 trial data &mdash; a reference point for what well-evidenced gut peptide pharmacology looks like</li>
              <li>The GC-C agonist class comparison (linaclotide vs. plecanatide) illustrates how structural differences produce different activity distribution in the gut</li>
            </ul>
          </div>
        </div>
      </div>

    </div>
  );
}
